Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Janus Henderson Group plc reports beneficial ownership of 5,348,395 shares of Glaukos Corp common stock. The filing states the shares are held by multiple Janus Henderson asset managers on behalf of managed portfolios and are reported with shared voting and dispositive power of 5,348,395 shares, representing 9.2% of the class. The filing disclaims rights to dividend or sale proceeds by the asset managers and identifies related exhibits for subsidiary classification.
Gilbert H. Kliman submitted a Form 144 notice related to common stock of the issuer. The filing shows an intended sale of 5,000 shares dated 05/14/2026 tied to an option granted 06/02/2016 and lists cash as the method. The filing also records a prior sale of 5,000 shares on 05/11/2026 for $675,000.00.
GLAUKOS Corp director Gilbert H. Kliman reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 5,000 shares of Common Stock at $24.69 per share and on the same day sold 5,000 Common Stock shares in an open-market sale at $135.00 per share.
After these transactions, he directly holds 35,528 Common Stock shares, which include 2,731 restricted stock units that are unvested or deferred. The option exercised was originally granted on June 2, 2016 and had fully vested by the first anniversary of the grant date.
GLAUKOS Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported an exercise-and-sell transaction in company stock. On April 30, 2026, he exercised stock options to acquire 10,000 shares of common stock at $38.68 per share, then sold 10,000 shares in open-market transactions at $140.00 per share.
Following these transactions, he directly owns 43,681 shares of common stock, which includes 5,230 restricted stock units that have not yet vested or been delivered. Both the sales and the option exercises were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating the activity was scheduled in advance.
GLAUKOS Corp executive Joseph E. Gilliam, the company’s President and COO, reported an open-market sale of 19,573 shares of common stock at a price of $143.54 per share.
After this transaction, he directly held 73,419 shares, which includes 43,925 restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp director Leana Wen reported an open-market sale of 1,700 shares of common stock at $143.35 per share. After this transaction, she directly holds 19,739 shares, which the filing states includes 2,731 restricted stock units that are unvested or with deferred delivery.
Glaukos Corporation is sharing an investor presentation that outlines its growth strategy, diversified ophthalmic pipeline and recent financial performance. The company highlights 12 commercialized products and 13 disclosed pipeline programs across glaucoma, keratoconus, blepharitis, myopia and retinal disease.
Net sales grew from $283 million in 2022 to $507 million in 2025, supported by innovations such as iStent, iDose TR and keratoconus therapies Photrexa and Epioxa. The presentation cites 30% 2025 topline growth, a 20% 10‑year revenue CAGR and roughly $800 million invested in R&D since 2018.
For 1Q 2026, Glaukos reports an adjusted gross margin of 84% and cash and equivalents of $281 million with no debt as of March 31, 2026. Sales guidance for 2026 has a midpoint of $627.5 million, underscoring expectations for continued expansion supported by global infrastructure in 17 countries and more than 300 commercial personnel.
Fidelity Brokerage Services LLC submitted a Form 144 notifying an intent to sell 19,573 shares of Common Stock of GKOS as reported on 05/01/2026. The shares arise from multiple restricted stock vesting events dated 12/13/2024 through 04/01/2025, with individual vesting amounts listed in the filing.